Aditxt Bets on Proteins to Reshape Its Future in Cancer Care

MOUNTAIN VIEW, CA – March 13, 2026 – Aditxt, Inc. has made a decisive move into the precision oncology arena, acquiring Ignite Proteomics in a deal valued at $36 million in stock. The acquisition signals a strategic pivot beyond traditional genetic markers, betting that the future of personalized cancer treatment lies in analyzing the functional activity of proteins within a tumor.

Ignite Proteomics, a commercial-stage company, brings a platform designed to address a critical gap in cancer care: selecting the right therapy for the right patient, especially when standard genomic tests fall short. The move is a high-stakes play for Aditxt, a self-styled “social innovation platform” whose own financial performance has drawn scrutiny from investors, but one that could position it at the forefront of a new diagnostic paradigm.

“Each year nearly 20 million people are diagnosed with cancer worldwide,” said Aditxt Co-Founder and CEO Amro Albanna in the initial announcement, underscoring the vast need. “We believe there is a real need for tools that can provide physicians with additional information to help support more informed treatment decisions, particularly as targeted therapies become more precise and more complex.”

Beyond the Genome: The Promise of Functional Proteomics

For years, precision oncology has been dominated by genomics—the science of sequencing a tumor’s DNA to find mutations that can be targeted by specific drugs. While revolutionary, this approach has limitations. A genetic mutation may not always result in a functionally active protein that a drug can attack. Ignite Proteomics aims to solve this problem by looking directly at the proteins themselves.

Ignite’s core technology is a Reverse Phase Protein Array (RPPA) platform. Instead of reading the genetic blueprint, this platform measures the actual expression and activation levels of 32 key proteins and phosphoproteins—the molecular machinery that drives cancer growth and signaling. This provides a direct snapshot of the active biological pathways in a tumor.

“For many cancers, the key clinical question is not only what mutations are present, but whether the relevant signaling pathways are actually active in the tumor,” noted Aditxt Co-founder and Chief Innovation Officer, Shahrokh Shabahang. “That is where functional proteomics can add value.”

Compelling evidence for this approach emerged from the I-SPY 2 clinical trial. Data presented at the 2025 NCCN Annual Conference showed that Ignite's RPPA-based measurement of MHC-II protein expression was a better predictor of patient response to the immunotherapy drug pembrolizumab than the five standard PD-L1 assays used for comparison. Such findings, along with ongoing collaborations with top-tier institutions like the Dana-Farber Cancer Institute and Vanderbilt University Medical Center, lend significant scientific weight to Ignite’s platform.

A High-Stakes Acquisition Amid Financial Turbulence

While the scientific premise is strong, the acquisition comes at a critical time for Aditxt. The company has faced significant financial headwinds, with InvestingPro data from late 2025 indicating a “WEAK” financial health score, staggering negative gross profit margins, and a stock price that had fallen nearly 100% over the previous year. The market reacted to the acquisition with skepticism, sending Aditxt’s stock (ADTX) tumbling over 37% following the news.

The deal, structured with 36,000 shares of Series A-2 Convertible Preferred Stock, cash payments, and promissory notes, is more than just a strategic expansion. It’s a move designed to help Aditxt shore up its balance sheet and meet the Nasdaq’s minimum stockholders’ equity requirement of $2.5 million, a critical step for maintaining its public listing.

This context frames the acquisition as a bold, perhaps necessary, gamble. Aditxt is leveraging its stock to acquire a company with potentially transformative technology, hoping that Ignite’s promise will rewrite its own financial narrative. The success of this bet hinges not just on the science, but on a clear path to market.

Paving a Commercial Path with Reimbursement

Ignite Proteomics arrives at Aditxt with a crucial advantage that sets it apart from many early-stage diagnostic firms: a clear and established commercialization framework. The company operates a CLIA-certified and CAP-accredited laboratory, the gold standard for clinical testing facilities in the United States.

Most importantly, Ignite possesses an established Medicare Proprietary Laboratory Analyses (PLA) reimbursement pathway. This provides a reimbursement rate of approximately $2,200 per test, a foundational element for driving clinical adoption and generating revenue. Without a clear reimbursement strategy, even the most innovative diagnostic tools can fail to gain traction in the healthcare system.

Ignite’s go-to-market strategy is a phased expansion focused on integrating its functional proteomics platform into oncology practices and Molecular Tumor Boards. The initial focus is on patient populations where conventional biomarker guidance is limited, such as patients with late-stage metastatic cancers who have exhausted standard treatment options. A collaboration with Inova Health to analyze up to 600 tumor samples from patients with late-stage gastrointestinal cancers is an early example of this strategy in action, providing real-world data to guide treatment decisions in the toughest cases.

Targeting a Multi-Billion-Dollar Unmet Need

The market opportunity for more advanced cancer diagnostics is substantial. The global cancer profiling market is estimated to be worth approximately $14 billion, with Ignite targeting a $3 billion serviceable opportunity among patients eligible for complex treatments like antibody-drug conjugates (ADCs) and other targeted therapies.

The rise of ADCs, which act like guided missiles to deliver potent chemotherapy directly to cancer cells expressing a specific protein target, has intensified the need for accurate protein-level diagnostics. Genomic tests can only suggest the potential for a protein to be present; Ignite’s platform aims to confirm its actual, functional presence.

By providing this missing piece of the puzzle, Aditxt and Ignite aim to become an essential infrastructure layer for modern cancer care. The acquisition fits squarely within Aditxt's stated “Discovery, Development, and Deployment” model, which has seen the company also acquire firms in infectious disease and pursue a merger in women’s health. By bringing Ignite into its fold, Aditxt is not just buying a technology; it is acquiring a potential solution to one of oncology's most pressing challenges and a new hope for its own future.